Department of Animal and Human Biology, University of Turin, via Accademia Albertina, 13, 10123 Turin, Italy.
Cardiovasc Res. 2011 Sep 1;91(4):617-24. doi: 10.1093/cvr/cvr129. Epub 2011 May 4.
Catestatin (CST) is a chromogranin A (CgA)-derived peptide (hCgA352-372) with three identified human variants (G364S/P370L/R374Q-CST) that show differential potencies towards the inhibition of catecholamine release. Although CST affects several cardiovascular parameters, the mechanisms underlying CST action in the heart have remained elusive. Therefore, we sought to determine the mechanism of action of CST and its variants on ventricular myocardium and endothelial cells.
Contractile force and Ca(2+) transients were measured, respectively, on rat papillary muscles and isolated cardiomyocytes (CC) under basal conditions and after β-adrenergic stimulation. Nitric oxide (NO) production and endothelial nitric oxide synthase (eNOS) phosphorylation (P(Ser1179)eNOS) were studied in bovine aortic endothelial (BAE-1) cells. Under basal conditions, wild-type CST (WT-CST, 10-50 nM) transiently enhanced myocardial contractility. CST variants (G364S and P370L) exerted a comparable positive inotropic effect. The H(1) histamine receptor antagonist mepyramine abolished the increase of contractile force induced by WT-CST. Moreover, WT-CST dose-dependently (5-50 nM) reduced the effect of β-adrenergic stimulation. This anti-adrenergic effect was not mediated by a direct action on CC, but involved a PI3K-dependent NO release from endocardial endothelial cells. Indeed, CST induced a wortmannin-sensitive, Ca(2+)-independent increase in NO production and eNOS phosphorylation on BAE-1 cells. While the anti-adrenergic and NO release effects of P370L-CST were comparable with those of WT-CST, the G364S variant was ineffective on the same parameters.
Our results suggest that the anti-adrenergic action of CST depends on the endothelial PI3K-Akt-eNOS pathway and that its structural alterations entail functional features that correlate with the different anti-hypertensive potential described in humans.
Catestatin (CST) 是一种源自嗜铬粒蛋白 A (CgA) 的肽 (hCgA352-372),具有三种已鉴定的人类变体 (G364S/P370L/R374Q-CST),它们在抑制儿茶酚胺释放方面表现出不同的效力。尽管 CST 影响了许多心血管参数,但 CST 在心脏中的作用机制仍然难以捉摸。因此,我们试图确定 CST 及其变体对心室心肌和内皮细胞的作用机制。
分别在大鼠乳头肌和分离的心肌细胞 (CC) 上测量基础条件下和β-肾上腺素能刺激后的收缩力和 Ca(2+) 瞬变。在牛主动脉内皮 (BAE-1) 细胞中研究了一氧化氮 (NO) 产生和内皮型一氧化氮合酶 (eNOS) 磷酸化 (P(Ser1179)eNOS)。在基础条件下,野生型 CST (WT-CST,10-50 nM) 短暂增强心肌收缩力。CST 变体 (G364S 和 P370L) 产生类似的正性肌力作用。H1 组胺受体拮抗剂甲吡嘧啶消除了 WT-CST 诱导的收缩力增加。此外,WT-CST 剂量依赖性地 (5-50 nM) 降低了β-肾上腺素能刺激的作用。这种抗肾上腺素能作用不是通过直接作用于 CC 介导的,而是涉及内皮层内皮细胞中 PI3K 依赖性的 NO 释放。事实上,CST 诱导wortmannin 敏感的、Ca(2+) 非依赖性的 NO 产生增加和 BAE-1 细胞中 eNOS 磷酸化。虽然 P370L-CST 的抗肾上腺素能和 NO 释放作用与 WT-CST 相当,但 G364S 变体在相同参数上无效。
我们的结果表明,CST 的抗肾上腺素能作用取决于内皮 PI3K-Akt-eNOS 途径,其结构改变带来的功能特征与在人类中描述的不同的抗高血压潜力相关。